PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents

Summary

The goal of this observational retrospective cohort study in combination with an expert study is to assess the clinical relevance and management of Lumen apposing metal stent (LAMS)-occlusion and LAMS-occlusion-related complications as well as the influence of proton pump inhibitors (PPI) on LAMS-occlusion.

The main questions this study aims to answer are:

* the individual management of LAMS-occlusion and LAMS-occlusion-related complications in the respective centers participating in the study.
* if there is an association between PPI-intake and LAMS-occlusion and endoscopic necrosectomies.

Participants for the retrospective cohort study will be enrolled retrospectively among European centers with expertise in pancreatology. The expert survey will be distributed European-wide to centers with special expertise in pancreatology.

Conditions

• Acute Pancreatitis

Interventions

DRUG

Proton pump inhibitor

Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not

DEVICE

LAMS-implantation

Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis

Sponsors & Collaborators

• Technical University of Munich

  collaborator OTHER

• Ludwig-Maximilians - University of Munich

  collaborator OTHER

• University Hospital in Halle

  collaborator OTHER

• University of Leipzig

  collaborator OTHER

• University Hospital Heidelberg

  collaborator OTHER

• Landesklinikum Sankt Polten

  collaborator OTHER

• University Hospital, Aachen

  collaborator OTHER

• University of Oldenburg

  collaborator OTHER

• University of Newcastle Upon-Tyne

  collaborator OTHER

• Szeged University

  collaborator OTHER

• University of Pecs

  collaborator OTHER

• Semmelweis University

  collaborator OTHER

• University of Ulm

  collaborator OTHER

• University Hospital Olomouc

  collaborator OTHER

• Brno University Hospital

  collaborator OTHER

• University Hospital Regensburg

  collaborator OTHER

• Klinikum Stadt Hanau

  collaborator OTHER

• University Medicine Greifswald

  collaborator OTHER

• University Medical Center Goettingen

  lead OTHER

Principal Investigators

• Jacob Hamm · Department of Gastroenterology, University Hopsital Goettingen

• Christoph Ammer-Herrmenau, MD · Department of Gastroenterology, University Hopsital Goettingen

• Volker Ellenrieder, Professor · Department of Gastroenterology, University Hopsital Goettingen

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-05-05

Primary Completion

2024-03-29

Completion

2024-03-29

Countries

• Germany